You just read:

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

News provided by

Astellas Pharma Inc.

Mar 26, 2018, 08:00 ET